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Simple Summary: Current therapies for pancreas carcinoma (PC) are of limited efficacy due to tumor
aggressiveness and therapy resistance. Bacterial toxins with pore-forming (oncoleaking) potential
are promising tools in cancer therapy. We have developed a novel, suicide gene therapy treatment,
based on Clostridium perfringens enterotoxin (CPE)-mediated oncoleaking. This is achieved by CPE
suicide gene therapy to treat PC, which overexpresses the claudin-3 and -4 (Cldn3/4) tight junction
proteins, which are targets of CPE action. This targeted gene therapy causes rapid eradication of
Cldn3/4 overexpressing PC cells via oncoleaking and initiation of apoptotic/necrotic signaling. We
demonstrate efficacy of this approach in vitro and after nonviral in vivo gene transfer in cell lines
and in patient derived xenograft PC models. This therapy approach has translational potential for
treatment of pancreas carcinomas and could also be translated into new combination settings with
conventional chemotherapy.
Abstract: Pancreatic cancer (PC) is one of the most lethal cancers worldwide, associated with poor
prognosis and restricted therapeutic options. Clostridium perfringens enterotoxin (CPE), is a pore-
forming (oncoleaking) toxin, which binds to claudin-3 and -4 (Cldn3/4) causing selective cytotoxicity.
Cldn3/4 are highly upregulated in PC and represent an effective target for oncoleaking therapy.
We utilized a translation-optimized CPE vector (optCPE) for new suicide approach of PC in vitro
and in cell lines (CDX) and patient-derived pancreatic cancer xenografts (PDX) in vivo. The study
demonstrates selective toxicity in Cldn3/4 overexpressing PC cells by optCPE gene transfer, mediated
by pore formation, activation of apoptotic/necrotic signaling in vitro, induction of necrosis and of
bystander tumor cell killing in vivo. The optCPE non-viral intratumoral in vivo jet-injection gene
therapy shows targeted antitumoral efficacy in different CDX and PDX PC models, leading to
reduced tumor viability and induction of tumor necrosis, which is further enhanced if combined
with chemotherapy. This selective oncoleaking suicide gene therapy improves therapeutic efficacy
in pancreas carcinoma and will be of value for better local control, particularly of unresectable or
therapy refractory PC.
Keywords: Clostridium perfringens enterotoxin (CPE); pancreatic cancer; gene therapy; suicide gene;
combination therapy
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1. Introduction
Pancreatic cancer (PC) is one of the leading causes of cancer death in developed
countries and one of the most lethal malignancies worldwide [1,2]. PC has one of worst
prognosis, reflected by a 5-year survival rate of less than 5% and median survival of less
than 6 months [3,4]. Despite advances in molecular and targeted therapies for improved
patient survival of many different tumor entities, the outcome for PC has not changed
much over the past 30 years. Monotherapy with gemcitabine is still the standard of
care therapy for PC [5], as no combination treatment—neither with 5-fluorouracil (5-FU),
cisplatin nor carboplatin—showed a significant increase of overall survival [6,7]. By
contrast, improvements for increased median overall survival were made by the 5-FU-
based triplet chemotherapy FOLFIRINOX (oxaliplatin, irinotecan, 5-FU and leucovorin) [8].
The only potentially curative treatment of pancreatic cancer is surgical resection, which can
lead to significantly longer survival compared to other treatment modalities [9].
Apart from all the established treatment modalities, gene therapy might be an alterna-
tive for an effective PC therapy. In particular, suicide gene therapy with use of bacterial
toxins is attractive. Bacterial toxins are produced and released by bacteria affecting dif-
ferent targets in host cells. An increasing number of in vitro and in vivo studies using
different bacterial toxins demonstrate efficacy in cancer cell killing [10]. During the last
years, improved processing and manipulation of bacterial toxins, such as diphtheria toxin,
streptolysin O or Clostridium perfringens enterotoxin (CPE) as well as their encoding gene
sequences translated into toxin-based cancer therapy [11–14].
CPE is of particular interest, since it allows effective and targeted attack of cancer cells.
The toxin is produced by the Gram-positive, anaerobic bacterium Clostridium perfringens [15].
This protein of 35 kDa comprises 319 amino acids. Its C-terminal receptor-binding domain
(cCPE, residues 194 to 319) recognizes and binds to the tight junction proteins claudin-3
and -4 (Cldn3/4). The N-terminal region of CPE is involved in oligomerization and pore
formation [16,17] and the cCPE domain mediates high-affinity binding to claudins. Pore
formation, however, is exclusively initiated by the N-terminal residues 80–160, known as
TM1 region [12,18–21]. High CPE concentration causes massive pore formation, which
leads to rapid Ca2+ influx and consequently to necrotic cell death. Low CPE concentration,
however, results in low pore numbers, rather leading to apoptotic cell death [21,22].
Numerous reports showed that compared to normal tissues, particularly epithelial
cancers, such as pancreatic, colon, ovarian, breast and prostate cancer possess high Cldn3/4
expression and dysregulation [23–25]. Based on this fact and regarding the cytotoxic
efficacy of CPE, considerable efforts were made to develop a CPE-based targeted cancer
therapy for Cldn3/4 overexpressing tumors. Numerous studies demonstrated that in vitro
and in vivo treatment with recombinant CPE exerted cytotoxic effects via pore formation
(oncoleaking) on high Cldn3/4 expressing pancreatic, ovarian and breast cancer cells,
which was associated with tumor reduction or elimination [26–28]. Since binding of CPE
to claudins is highly specific, this toxin is attributed with great potential for targeted
gene therapeutic treatment of Cldn3/4 overexpressing tumors [29,30]. Based on this,
we exploited CPE as a valuable option for therapy refractory tumors such as pancreas
carcinoma. In this study we used the toxin in a suicide gene therapy approach for efficient
and targeted eradication of Cldn3/4 overexpressing PC as a novel oncoleaking therapy
in vitro and more importantly in vivo.
2. Materials and Methods
For comprehensive and detailed description of all methods see Supplementary Meth-
ods.
2.1. Cell Lines
Human pancreas carcinoma AsP-1, BxPC-3, Capan-1 and Sk-Mel-5 melanoma cells
were grown in RPMI medium (Gibco, Life technologies, Darmstadt, Germany), 10% FCS
(Biochrom, Berlin, Germany). The human pancreas carcinoma HUP-T3, MIA PaCa-2,
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PA-TU-8902 and human colon carcinoma HT-29 cells were grown in DMEM (Gibco), 10%
FCS (Biochrom). All lines were kept at 37 ◦C, 5% CO2. The identity of all cell lines was
confirmed by STR-genotyping (DSMZ, Braunschweig, Germany).
2.2. Pancreatic Cancer Patient Derived Xenograft (PDX) Models
For in vivo studies, 21 pancreas carcinoma PDX models of stage IV (EPO Berlin-Buch
GmbH, Berlin, Germany), were used [31].
2.3. Quantitative Real-Time RT-PCR
Total RNA was isolated using GeneMatrix Universal RNA Purification Kit EURx
(Roboklon, Berlin, Germany) and reverse transcribed. Quantitative real-time PCR (qPCR)
was performed with SYBR GREEN in the LightCycler 480 (Roche Diagnostics, Mannheim,
Germany). They following primers were used for claudin-3: forward 5′-CTGCTCTGCT
GCTCGTGTCC-3′; reverse 5′-TTAGACGTAGTCCTTGCGGTCGTAG-3′; for claudin-4: for-
ward 5′-CCTCTGCCAGACCCATATAA-3′; reverse 5′-CACCGTGAGTCAGGAGATAA-3′;
for RNA polymerase II: forward 5′-GCACCACGTCCAATGACA T-3′, reverse 5′-GTGCGGC
TGCTTCCATAA-3′. Normalization was done with the housekeeping gene glucose-6-
phosphate dehydrogenase (G6PDH) using the hG6PDH Roche Kit (Roche Diagnostics).
Primers used for G6PDH: forward 5′-GAAGATGGTGATGGGATTTC-3′, reverse 5′-GAAG
GTGAAGGTCGGAGT-3′.
2.4. Western Blot
Cells or tissue cryosections were lysed in RIPA buffer (50 mM TRIS, 150 mM, NaCl,
1% Nonidet P-40, 0.5% sodiumdeoxycholate, protease inhibitor, ddH2O). For isolation
of membrane, cytosolic and nuclear fractions the Cell Fractionation kit (Cell Signaling,
Frankfurt, Germany) was used. Lysates were electrophoresed in 10% precast NuPAGE gels
(Invitrogen, Waltham, MA, USA) and transferred to nitrocellulose membranes. Membranes
were blocked for 1 h at room temperature in TBS (50 mM Tris, 150 mM NaCl, pH 7.5, 5% fat-
free dry milk and 2.5% casein) and washed in TBST (0.05% Tween 20 in PBS). Western blot
was performed with primary rabbit anti-claudin-3 antibody (Acris, Origene Technologies,
Rockville, MD, USA), rabbit anti-claudin-4 antibody (Acris), rabbit polyclonal anti-CPE
(BioRad, Hercules, CA, USA), mouse monoclonal anti-β-tubulin (BD Bioscience, East
Rutherford, NJ, USA) or mouse monoclonal anti-β-actin antibody (Pierce, Thermo Fisher
Scientific, Waltham, MA, USA). As secondary HRP-labeled goat anti-rabbit-IgG antibody
(Promega, Madison, WI, USA), HRP-labeled goat anti-mouse-IgG antibody (Pierce,) or goat
anti-mouse IgM/IgG (Sigma-Aldrich, Merck, St. Louis, MI, USA) was added. Detection
was done using ECL solution (Amersham, GE Healthcare, Chicago, IL, USA) and exposure
to Kodak X-Omat AR film (Kodak, Stuttgart, Germany).
2.5. Clostridium Perfringens Enterotoxin (CPE) Expressing Plasmids
For transfection experiments the translation optimized pCpG-optCPE (optCPE) and
the pcDNA3-CPE-GFP (CPE-GFP) plasmids were used [29,30]. Preparation of plasmid-
DNA was done by Jetstar Plasmid Purification Maxi Kit (Genomed, Löhre, Germany).
2.6. Transfection of Cells with Plasmid DNA and siRNA
For transfection experiments, the pCpG-optCPE (optCPE) or the pCpG-mcsG2 empty
vector control (VC) plasmid (Invivogen, San Diego, CA, USA) was used. A mutated optCPE
construct unable to bind Cldn3/4 (mutCPE, CPE-Y306A/L315A; Figure S1) was used for
in vivo selectivity testing [20,21,32–34]. For transfections, 3 × 105–5 × 105 cells/well were
seeded in 6-well plates and after 24 h transfected with respective plasmid DNA plus
transfection reagent (FuGene, X-treme, Metafectene, TransIT) according to manufacturer’s
instruction. After 12–72 h, cells were washed with PBS and RNA or protein was isolated.
Knockdown of Cldn3/4 was done with pools of three different iBONi short interfering
RNAs (siRNA) for Cldn3 or 4. For siRNA knockdown, 3 × 105 cells were seeded in 6-well
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plates and 24 h later transfected with 50 nM siRNA plus 7 µL Lipofectamine RNAiMAX
Reagent (Thermo Fisher Scientific, Waltham, MA, USA). Cells were washed with PBS 48 h
or 72 h post transfection and RNA and protein was isolated.
2.7. MTT Cytotoxicity Assay
MTT assay was used to test cytotoxicity of recombinant CPE (recCPE) or of optCPE
transfection and to test cytotoxicity of released CPE from transfected cells. For sensitivity
testing of cell lines towards recCPE 6 × 103–4 × 105 cells were seeded into 96-well plates
and 24 h later 0, 50, 100, 150 ng mL−1 recCPE was added and incubated for 72 h. For
determination of toxicity of released CPE in supernatants of transfected cells, 6 × 103
non-transfected cells were seeded into 96-well plates. After 24 h, 100 µL of supernatants
from optCPE-transfected cells were added to respective non-transfected cells and incubated
for 72 h. For all cytotoxicity assays, 5 mg mL−1 MTT (3-(4,5-dimethylthiazyol-2yl)-2,5-
diphenyltetrazolium bromide; Sigma) was added 72 h after CPE incubation. Absorbance
was measured in triplicates at 560 nm in a microplate reader (Tecan, Groedig, Austria) and
values are expressed as percentage of untreated controls.
2.8. CPE ELISA
For quantification of CPE in supernatants 24 h or 48 h after transfection, Ridascreen
Clostridium perfringens enterotoxin ELISA (R-Biopharm, Darmstadt, Germany) was per-
formed. For this, 4 × 105 cells were seeded into 6-well plates and transfected with pCpG-
optCPE or pCpG-mscG2 plasmid-DNA. Recombinant CPE was used as standard at serial
dilutions of 0.4–25 ng CPE mL−1. Measurements were done in duplicates at 450 nm in the
microplate reader (Tecan) and values are expressed as percentage of untreated controls.
2.9. Immunocytochemistry, Immunohistochemistry and Immunofluorescence
For immunohistochemistry, 2 × 105 cells were seeded into 4-well chamber slides and
after 24 h washed with PBS, fixed in 4% paraformaldehyde (PFA, Pierce Thermo Fisher
Scientific) in PBS for 15 min, permeabilized with 0.5% Triton-X in PBS for 10 min and
blocked with 1% IgG-free albumin (Sigma Aldrich, Taufkirchen, Germany) and 0.05%
Tween-20 in PBS for 1 h. Rabbit anti-human Cldn3 or anti-human Cldn4 antibody (Acris)
was added as primary antibody, cells were washed with TBST, then incubated with HRP-
conjugated goat anti-rabbit IgG antibody (Promega, Madison, WI, USA), washed again
and incubated with diamino-benzidine (DAB, DAKO, Hamburg, Germany). Cells were
then washed in ddH2O, counterstained with hemalum (Roth) and evaluated in a light
microscope (Zeiss, Jena, Germany).
For immunofluorescence, 2 × 105 cells were seeded onto cover slips (Steiner GmbH,
Siegen Eiserfeld, Germany), washed, fixed in 4% PFA, quenched with 0.1 M glycine for
20 min and blocked with 1% serum-free albumin, 0.05% Tween-20 for 1 h. The respective
primary goat anti-claudin-3 rabbit polyclonal IgG (Abcam, Cambridge, UK), goat anti-
claudin-4 rabbit polyclonal IgG (Santa Cruz, Dallas, TX, USA) anti-CPE rabbit polyclonal
IgG, (BioRad) was added, cells were washed with TBST and incubated with secondary
antibody (goat anti-rabbit-Alexa 488, goat anti-rabbit-Alexa 555, goat anti-rabbit-Alexa 647,
donkey anti-goat-Alexa 555 and donkey anti-goat-Alexa 647 antibodies, all from Thermo
Fisher). Nuclei were stained with DAPI (Sigma-Aldrich), counterstained with Alexa 555-
phalloidin (Thermo Fisher Scientific) and evaluated in a confocal fluorescence microscope
(Zeiss).
For analysis of Cldn3/4 expression or CPE expression after gene transfer in the PDX
tumors, 3–5 µm thick paraffin embedded (FFPE) tumor sections were deparaffinized, fixed
with 4% PFA, quenched with 0.1 M glycine for 20 min, incubated with 3% H2O2 for 10 min,
washed with PBS, permeabilized by 0.2% Triton X-100 and blocked with 1% IgG-free
albumin and 0.05% Tween-20 for 1 h. Steps for staining are similar to aforementioned
procedure.
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2.10. In Vivo optCPE Gene Transfer
For establishment of subcutaneous tumors, 1 × 106 cells or pieces of approximately
3 × 3 mm in size of patient derived pancreas cancer PDX tissue were inoculated into
the left flank of female NMRI: nu/nu mice (n = 5 animals per group). Animals were
randomized at tumor volume of 0.3 cm3 and intratumoral non-viral in vivo jet injection
gene transfer (jet injector, EMS Medical Systems SA, Nyon, Switzerland) was performed
in anesthetized animals [35]. For this, 50 µg plasmid DNA of respective vector construct
was applied once by 5 injections (1 µg DNA µL−1 PBS in 10 µL injection volume). Tumor
volumes (TV) were measured at indicated time points and calculated using the formula:
TV = (width2 × length)/2. Animals were sacrificed and tumors were harvested for further
analysis. Body weights, clinical signs and behavior were recorded for all mice twice a
week. All experiments were performed in accordance with the UKCCCR guidelines and
approved by local authorities (State Office of Health and Social Affairs, Berlin, Germany,
approval No. Reg0010/19).
2.11. Statistical Analysis
For statistical analyses of the in vitro experiments the Student’s t-test and one way-
ANOVA test were used. For the statistical analyses of in vivo experiments the non-
parametric, unpaired t-test was used. Error values for the in vitro experiments are S.D. and
for in vivo experiments S.E.M.
3. Results
3.1. Cldn3/4 Expression in Human Pancreas Carcinoma Cell Lines
Prerequisite for targeted antitumoral oncoleaking activity of CPE is presence of high
affinity CPE receptors, such as Cldn3/4, as the CPE-mediated cytotoxicity requires their
accessibility. This was analyzed in a panel of human PC cell lines at mRNA and protein level.
By this, Capan-1, PA-TU-8902, AsPc-1 and the positive control human colon cancer HT-29
control cells showed high Cldn3/4 mRNA levels, whereas moderate levels of Cldn3/4 were
detected in MIA PaCa-2 and HUP-T3 cells (Figure 1A). BxPC-3 cells revealed low Cldn3
expression and moderate Cldn4 expression. The negative control human melanoma cell
line SK-MEL-5 did not express Cldn3/4. Western blot, IHC and also immunofluorescence
imaging revealed heterogeneous distribution of Cldn3/4 in Capan-1, HUP-T3, MIA PaCa-2
and Pa-TU-8902 cells (Figure 1A–C): apart from membranous presence, both claudins were
also detected in the cytoplasm and the nucleus.




Figure 1. Claudin-3 (Cldn3) and claudin-4 (Cldn4) expression and distribution analysis and sensitivity toward recombi-
nant CPE (recCPE) in human PC cell line panel. (A) Quantitative real time PCR (qRT-PCR, graph upper panel) and West-
ern blot analyses (two lower panels for claudin and β-actin, Figure S5) for Cldn3 (left) and Cldn4 (right). The human 
Figure 1. Cont.
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i r 1. laudin-3 (Cldn3) and claudin-4 (Cldn4) expression and istribution an lysis and sen itiv y toward recombinant
CPE (recCPE) in human PC cell lin panel. (A) Quantitative real time PCR (qRT-PC , graph upper panel) and Western blot
analyses (two lower panels for claudin and β-actin, Figure S5) for Cldn3 (left) and Cldn4 (right). The human colorectal
cancer cell line HT-29 served as positive control and the human melanoma cell line SK-MEL-5 as negative control with
no Cldn3/4 expression. Data are represented as mean values ± S.D. (n = 3). (B) Representative immunohistochemistry of
Cldn3 (left) and Cldn4 (right) in respective pancreatic cancer cell lines, demonstrating different distributions of Cldn3/4
(brown). (C) Western blot analysis of cell fractions from four PC cell lines using Cldn3/4, and Lamin B1, showing whole cell
lysates, cytoplasmic, membrane and nuclear localization (Lamin B1 marker nuclear fraction, Figure S5). Representative
immunofluorescence images (right panel) of respective cell lines, confirming diverse Cldn3 (yellow) and Cldn4 (red)
expression in different cell compartments (scale bar = 25 µm). DAPI and actin staining was used for nuclei and cytoplasm,
respectively. (D) Sensitivity toward recCPE at 72 h post treatment using MTT assay and compared to untreated/solvent
treated controls with strong cytotoxic effects in all PC cell lines and positive control line HT-29. SK-MEL-5 negative control
cells remained unaffected. MTT data are represented as mean values ± S.D. (n = 6), expressed as mean percentage of
untreated control. (ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
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3.2. Sensitivity of Pancreas Carcinoma Cells toward Recombinant CPE
For sensitivity testing of Cldn3/4 expressing pancreatic cancer cell lines toward re-
combinant CPE (recCPE) protein, increasing recCPE concentrations from 0 to 250 ng mL−1
were applied for 72 h and cytotoxicity was measured (Figure 1D). High Cldn3/4 expressing
Capan-1 and AsPC-1 cells as well as HUP-T3 cells with moderate Cldn3/4 expression
showed a significant (p = 0.0001) dose dependent sensitivity toward recCPE. Despite high
Cldn3/4 expression level, PA-TU-8902 cells showed comparatively low sensitivity toward
recCPE, since the highest concentration reduced cell viability only to 60% (p = 0.0019).
By contrast, in BxPC-3 and MIA PaCa-2 cells with low Cldn3/4 expression, higher cy-
totoxicity was measured. In these cells viability was significantly (p = 0.0001) reduced
to 40% or 32% compared to control, respectively. However, Cldn3/4 negative cell line
SK-MEL-5 was insensitive towards the toxin. RNAi-mediated downregulation of Cldn3/4
expression in MIA PaCa-2 and HUP-T3 cells transfected with siCldn3 and siCldn4 or
siCtrl, abolished sensitivity toward recCPE (Figure S2). All this points to the fact, that both
claudin expression and accessibility outside tight junctions is important to mediate CPE
cytotoxicity.
3.3. CPE Gene Transfer Permits Effective and Selective Cell Killing
To evaluate antitumoral efficacy of CPE gene transfer, first presence and expression
kinetic for CPE was analyzed. After gene transfer, the immune fluorescence in Capan-1,
HUP-T3 and PA-TU-8902 cells showed strong cytoplasmic staining for CPE (Figure 2A).
Furthermore, Western blot analyses revealed strong and time-dependent CPE expression
starting 24 h after gene transfer and lasting for up to 72 h (Figure 2B). Next, we determined
CPE gene transfer mediated selective tumor cell killing in Cldn3/4 positive Capan-1,
PA-TU-8902, AsPc-1, MIA PaCa-2, BxPC-3 and HUP-T3 cells as well as the negative
control cell line SK -MEL-5 and the positive control line HT-29. The experiments showed
significant toxicity by optCPE expression in all Cldn3/4 positive cells with toxicity rates of
40–85%, except for AsPc-1 (Figure 2C). The Cldn3/4 negative cell line SK-MEL-5 remained
unaffected after gene transfer, indicating strict claudin-selectivity of optCPE cytotoxicity.




Figure 2. Expression of optCPE and selective cytotoxicity after in vitro gene transfer. (A) Representative immunofluores-
cence images showing expression of optCPE (green) 12 h after transfection in Capan-1, HUP-T3 and PA-TU-8902 cells (40-
fold magnification). Cytoplasm was stained with phalloidin (red) and nuclei with DAPI (blue). The images reveal strong 
Figure 2. Cont.
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Figure 2. Expression of optCPE and selective cytotoxicity after in vitro gene transfer. (A) Representative immunofluores-
cence images showing expression of optCPE (green) 12 h after transfection in Capan-1, HUP-T3 and PA-TU-8902 cells
(40-fold magnification). Cytoplasm was stained with phalloi in (red) and nuclei with DAPI (blue). The image eveal
strong CPE expression, with vesicle-like cytoplasmic accumulation, localization on cell membrane and cell contact regions.
(B) Kinetic of optCPE expression in Capan-1, HUP-T3, MIA PaCa-2 and PA-TU-8902 cells 24 to 72 h after transfection
(Figure S6). (C) Cytotoxicity of optCPE and vector control (VC) gene transfer was analyzed by MTT assay 72 h after
transfection. All transfected Cldn3/4 expressing cells showed significant optCPE toxicity. SK MEL-5 negative control cells
remained unaffected, supporting selectivity of optCPE. Data are represented as mean values ± S.D. (n = 6), expressed as
mean percentage of VC treated cells. (D) Rescue experiment in MIA PaCa-2 and HUP-T3 cells transfected with a pool of
two specific small interfering RNAs or respective control (siCtrl), leading to efficient knockdown of Cldn3/4 at protein
level (Western blot, (Figure S6). (E) Cldn-silenced cells were transfected with optCPE. MTT assay was performed 72 h
later showing significantly reduced CPE cytotoxicity in MIA PaCa-2 and HUP-T3 cells compared to siCtrl treated cells,
demonstrating selectivity optCPE. Data are represented as mean values ± S.D. (n = 2), expressed as mean percentage of
siCldn3/4 treated cells. (ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
To further prove selectivity of CPE cell killing, RNAi experiments were performed
for specific downregulation of Cldn3/4 expression. MIA PaCa-2 and HUP-T3 cells were
transfected with a pool of siCldn3 and siCldn4 or siCtrl, respectively (Figure 2D). The
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downregulation of Cldn3/4 led to reduction of protein expression in both lines 48 h after
transfection (Figure 2D), with most pronounced effects for Cldn4 silencing. The Cldn3/4-
silenced cells were transfected with optCPE expressing vector and cytotoxic effect was
determined 72 h after transfection. By this, optCPE-mediated cytotoxicity was significantly
reduced in Cldn3/4-silenced MIA PaCa-2 and HUP-T3 cells compared to siCtrl-transfected
cells (p < 0.001; Figure 2E). These data support the selective, Cldn-targeted activity of
optCPE gene transfer.
3.4. Analysis of Rapid Oncoleaking Cell Death Mechanism by CPE Gene Transfer
For the improved and more effective use of the pore-forming toxin, the mode of cell
death by CPE gene therapy was of interest. We determined timely activation of apoptotic
or necrotic pathways in optCPE-transfected pancreatic cancer cells by live cell imaging for
apoptotic signaling, Ca2+ influx due to pore formation, activation of caspase-3 and binding
of Annexin-V to apoptotic cells. Furthermore, lactate dehydrogenase (LDH) release and
calpain activation was determined.
The first indication for optCPE action is uncontrolled calcium influx. In MIA PaCa-2
and PA-TU-8902 cells optCPE gene transfer induced rapid calcium influx indicating rapid
pore formation between 8 and 14 h after gene transfer, although to different extents in the
two lines (40- to 100-fold increase; Figure 3A). Further, in both cell lines LDH is released
after optCPE gene transfer with highest values (3- to 13-fold) at 48 h (Figure 3B). These two
parameters strongly indicate membrane leakiness and disruption. Such optCPE activity
is paralleled by initiation of apoptotic events. In this context, we observed a dramatic
increase in annexin V positivity within 6 h after gene transfer in the two lines as a strong
indicator for apoptosis (Figure 3C). This was further supported by increased caspase 3/7,
−8 and −9 activation as early as 12 to 14 h after the gene transfer (Figure 3D). This increase
in caspase activation was also accompanied by the increased calpain 1/2 activity. This
results in strong activation of cell apoptosis and necrosis and associates with the dramatic
calcium influx (Figure 3E). This was further supported by apoptosis array analysis showing
upregulation of not only pro-caspase 3 but also cytochrome C, SMAC/diabolo, Bax, etc.
(Figure S3). All these cellular events point to the effective, rapid activation of apoptotic
signaling by optCPE gene transfer leading to the efficient killing of pancreatic cancer cells.
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lactate dehydrogenase (LDH): liberated LDH was analyzed in vector control (VC) or optCPE-transfected MIA PaCa-2 (left)
and PA-TU-8902 cells (right). The experiment revealed a 1.5-fold and 3-fold increase of LDH release in optCPE expressing
MIA PaCa-2 cells 20 h or 48 h after transfection, respectively. PA-TU-8902 cells showed higher LDH release starting 14 h
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with subsequent decrease compared to VC-transfected cells. Data are represented as mean values ± S.D. (n = 3), expressed
as relative caspase activity n-fold to VC. (E) Analysis of calpain-1/2 activation in optCPE expressing PC cell lines. Both lines
revealed significant high calpain-1/2 activation 14–24 h after optCPE transfer. Data are represented as mean values ± S.D.
(n = 3), expressed as calpain-1/2 activity/µg protein. (ns: not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p = 0.0001).
3.5. Mechanism of Bystander Effect in CPE Gene Therapy
The transfection experiments revealed much higher optCPE toxicity than anticipated
by transfection rates of 10–65% of the human PC cell lines. This suggests that non-
transfected cells are potentially affected by a bystander effect of released optCPE. To prove
this, supernatants of optCPE-transfected cells were examined. First, we analyzed cytotoxic-
ity of the supernatants released 24 h, 48 h and 72 h after optCPE transfection of PA-TU-8902
and MIA PaCa-2 pancreas cancer cells (Figure 4A). By this, viability of PA-TU-8902 cells
dramatically dropped to 25% and 18%, respectively. MIA PaCa-2 cell viability dropped
to only 75%. These results correlate with optCPE amounts in the supernatants. High
amounts of released optCPE in supernatant of PA-TU-8902 cells (24 h = 441.15 ng mL−1,
48 h = 614.25 ng mL−1, 72 h = 661.97 ng mL−1) induced strong cytotoxicity. The lower
toxin amount, released by MIA PaCa-2 cells (24 h = 277.51 ng mL−1, 48 h = 320.43 ng mL−1,
72 h = 272.24 ng mL−1) resulted in lower cytotoxicity.
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Figure 4. Analysis of bystander effect and of CPE release via exosomes in optCPE-transfected PC cells. (A) Analysis of
cytotoxicity of released optCPE. Media of vector control (VC) or optCPE-transfected MIA PaCa-2 and PA-TU-8902 cells
collected at 24 h, 48 h and 72 h were added to respective non-transfected cells. After 72 h cytotoxicity was determined by
MTT. Significant reduction of viability in PA-TU-8902 and MIA PaCa-2 cells was induced by supernatants collected 48 h
and 72 h after transfection. For PA-TU-8902 cells, higher toxicity was observed than in MIA PaCa-2 cells. This correlated
with the released optCPE amount. (B) Western blot of supernatant and exosomes (specific exosomal marker heat shock
protei 70, HSP70 and tetraspani CD63, Figure S7) from transfected MIA PaCa-2 and PA-TU-8902 cells. (C) Quantification
of optCPE within supernatant and exosomes of optCPE-transfected MIA P Ca-2 and PA-TU-8902 cells by CPE ELISA
revealed concentrations of 324.4 and 382.7 ng mL−1 CPE in supernatant and 242.6 and 344.5 ng mL−1 CPE in exosomes,
respectively. Data are represented as mean values ± S.D. (n = 3), expressed as mean percentage of VC. (* p < 0.05; ** p < 0.01;
**** p < 0.0001).
To determine if optCPE is releas d via exosomes, media of optCPE-transfected MIA
PaCa-2 and PA-TU-8902 cells were used for exosome isolation. Successful isolation was
controlled by specific exosomal marker heat shock protein 70 (HSP70) and tetraspanin
CD63 in the Western blot (Figure 4B). Both, supernatants and enriched exosomes showed
optCPE presence. Quantification of optCPE revealed CPE concentrations of 324.4 and
382.7 ng mL−1 in supernatant of transfected MIA PaCa-2 and PA-TU-8902 cells and 242.6
and 344.5 ng mL−1 CPE in exosomes, respectively (Figure 4C). This supports the CPE
release from transfected cells via exocytosis as well as exosomes, which in turn mediates
the bystander effect. All these data clearly support the efficiency of optCPE gene therapy,
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mediated by prolonged toxin presence and the bystander effect, permitted by CPE release
for cancer cell eradication.
3.6. In Vivo Kinetic and Antitumoral Effects of CPE In Vivo Gene Transfer
For analysis of time dependent expression and dispersion of optCPE after intratumoral
in vivo gene transfer the CDX models PA-TU-8902 or MIA PaCa-2 were used. For this,
mice were jet-injected intratumorally with optCPE expression vector and 24, 48, 72 and 96 h
after gene transfer animals were sacrificed and optCPE gene expression was determined
by Western blot, CPE-ELISA and IHC (Figure 5A,B). Western blot analysis of PA-TU-8902
tumors showed moderate optCPE expression 24 h after gene transfer with peak at 96 h.
This was confirmed by quantification of expressed optCPE with values of 0 ng mL−1 at 24 h
to 290 ng mL−1 optCPE after 96 h (Figure 5A,B). MIA PaCa-2 tumors showed high optCPE
expression from 24 h after gene transfer on (between 130–250 ng mL−1 optCPE), which
decreased over time to 2–14 ng mL−1 optCPE (Figure 5A,B). IHC further validated the
intratumoral presence of expressed optCPE (brown staining). Examination of all tumors
via HE staining showed massive tissue destruction within the transfected tumor. This is
reflected by the ratio of vital vs. necrotic tissue areas (Figure 5C), indicating more than 50%
necrosis of tumors as early as 24 h after gene transfer.
3.7. Oncoleaking Efficacy of In Vivo CPE Gene Transfer
Next, we investigated the antitumoral effect in high and low Cldn3/4 expressing
human pancreatic CDX models. In the Cldn3/4 low expressing MIA PaCa-2/eGFP-Luc
tumors non-viral optCPE gene transfer led to significant reduction of tumor viability
(p = 0.0336) and tumor volume (p < 0.0001) compared to vector control (VC) treated
mice (Figure 6A,B). This was also reflected by reduced in vivo and ex vivo biolumines-
cence signals in optCPE expressing tumors (Figure 6C,D). In high Cldn3/4 expressing
Capan-1/eGFP-Luc CDX tumor bearing mice jet-injection optCPE gene transfer also led to
significant reduction of tumor viability reflected by the reduced tumor bioluminescence
signals in vivo and ex vivo (Figure 6E,G,H). By contrast, tumor volume seemed to be
unaffected (Figure 6F). Based on our previous observation for CPE action this points to
rapid and massive necrosis in these tumors with reduced viability and slightly changed
tumor volumes.
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Figure 6. Therapeutic efficacy of no -viral in vi o optCP e e transfer. (A) 34 days after cell injection of optCPE gene
transfer (GT) was performed. By this, significant inhibition of tumor viability (determined by bioluminescence; BL), and
(B) tumor growth (measured via mean tumor volume) was observed in MIA PaCa-2/eGFP-Luc bearing mice compared to
VC-transfected animals. (C) Decrease of BL in optCPE-transfected tumors compared to controls, shown in representative
images. (D) Ex vivo t mor BL showed significantly reduced tumor viability at day 39. Data represent mean valu s ± S.E.M.
(n = 10). (E) Reduction of tumor viability of Capan-1/eGFP-Luc CDX tumors (determined by tumor BLI) was observed
after intratumoral optCPE gene transfer (performed 26 days after cell injection). (F) Mean tumor volume was not affected
by intratumoral optCPE expression. (G) Decrease of BL in optCPE-transfected CDX tumors compared to respective
vector control (VC), shown by representative images. (H) At day 36 ex vivo tumor BL was determined (n = 7), showing
significantly reduced viability. (I) After intratumoral optCPE gene transfer (performed 23 days after tumor cell injection),
significant antitumoral efficacy was shown in PA-TU-8902/eGFP-Luc CDX-bearing mice. Tumor viability (determined
by tumor BL) decreased significantly in optCPE-expressing tumors compared to empty vector control (VC) or the non-
Cldn3/4 binding CPE (mutCPE) expressing tumors. (J) Similarly, in vivo optCPE gene transfer significantly inhibited
of PA-TU-8902/eGFP-Luc CDX tumor growth compared to VC or mutCPE gene transfer, respectively. (K) Tumor BL
revealed reduced tumor viability by reduction of BL signals in optCPE-transfected CDX tumors compared to respective
controls, shown in representative images. (L) Ki67 analysis (brown staining, indicated by arrows) shows decrease in
optCPE-transfected groups (not significant). (M) In optCPE-transfected PA-TU-8902/eGFP-Luc CDX tumors TUNEL
assay shows significantly increased number of TUNEL positive nuclei (brown staining, indicated by arrows) compared
to mutCPE or VC-transfected tumors. All data represent mean values ± S.E.M. (n = 8). The level of significance was
determined using One way ANOVA based on one characteristic or factor (different treatments) or Two way-ANOVA based
on multiple characteristics (e.g., different treatments at different time points) and Turkey’s multiple comparison post-test or
the nonparametric Mann-Whitney U-test based on comparison of two groups. (n.s. not significant; * p < 0.05; ** p < 0.01;
*** p < 0.001; **** p = 0.0001).
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In summary, intratumoral optCPE gene transfer exerted significant antitumoral ac-
tivity. This leads to decreased tumor viability and increased tumor growth inhibition in
the human pancreatic cancer CDX models with comparable degree, independent of the
Cldn3/4 expression level.
3.8. In Vivo Selectivity of CPE Gene Therapy and Mechanism of In Vivo Action
To address selectivity of in vivo optCPE action, an expression plasmid with mutated
optCPE (mutCPE, Figure S1; generated by side directed mutagenesis) was used as control.
This mutCPE has almost no binding affinity to Cldn3/4 and supports claudin-selectivity
of CPE action [32,33]. In PA-TU-8902/eGFP-luc s.c. tumor bearing mice non-viral intra-
tumoral jet-injection gene transfer was performed and tumor viability was measured by
bioluminescence. In optCPE-transfected tumors bioluminescence was significantly reduced
compared to mutCPE (p = 0.0257) or VC (p = 0.0003)-transfected tumors (Figure 6I–K).
This was supported by significant tumor growth inhibition in optCPE-transfected tumors
compared to VC (p < 0.00001) and mutCPE (p = 0.0004)-transfected tumors. The mutCPE-
mediated effects were not different from the VC-transfected group. This validates the
strict Cldn3/4 selectivity of optCPE cytotoxicity after intratumoral in vivo gene transfer as
important feature for targeted gene therapy.
Since knowledge on the mechanism of action of intratumorally expressed optCPE is
limited, the potential induction of apoptosis or necrosis in the treated tumors was analyzed.
In this regard, Ki67 reactivity was determined by IHC staining in gene-transfected tumor
tissue to evaluate proliferation inhibition (Figure 6L). By this, no significant difference
in Ki67 activity was detected between VC, mutCPE or optCPE-transfected tumor tissue.
Therefore, optCPE has no impact on cell proliferation in the PA-TU-8902/eGFP-Luc CDX
tumors. Further, to detect in situ fragmented DNA as key characteristic of apoptosis, termi-
nal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed.
By this, a significantly increased number of TUNEL positive nuclei was determined in
optCPE-transfected PA-TU-8902/ eGFP-Luc tumors compared to mutCPE (p = 0.0041) or
VC (p = 0.0009)-transfected tumors. This was particularly seen in areas, with close vicinity
to necrotic areas, which could partially be explained by the optCPE-mediated bystander
effect (Figure 6M). All this strongly indicates claudin-selectivity in vivo for induction of
tumor apoptosis and necrosis.
3.9. Oncoleaking CPE Gene Therapy in Pancreas Carcinoma PDX
To extend our gene therapy approach beyond established CDX models, a panel
of 21 human pancreatic cancer PDX was characterized regarding Cldn3/4 expression
and histopathological features (Figure 7). Primary tumors and respective PDX tissues
were analyzed by HE staining. Pancreatic cancer PDX tissues were found to possess
similar histological appearance as the corresponding primary tumor tissue: atypical glands,
desmoplasia or pleomorphism of nuclei (Figure 7B). PCR expression analysis and Western
blot of all 21 PDX models showed Cldn3/4 expression (Figure 7A). This was further
confirmed by IHC for Cldn3/4, showing the specific membranous expression within the
pancreatic cancer PDX tissue (Figure 7B). This is a strong indication that the target for CPE
action is expressed in all of these pancreas cancers.
Next, in vivo experiments were performed using the Panc12536 PDX model, sta-
bly transduced with eGFP-Luc luciferase expressing vector. In the in vivo transfected
Panc12536/eGFP-Luc bearing mice antitumoral activity of optCPE was observed, since
tumor viability (determined by tumor bioluminescence) was significantly reduced in these
tumors compared to VC (p = 0.0007, Figure 7C–E). This was paralleled by significant
tumor growth inhibition (p = 0.0142) compared to VC-transfected tumors (Figure 7F).
Furthermore, 27 days after gene transfer the ex vivo bioluminescence signal of optCPE
expressing tumors showed significantly decreased intensity (p = 0.014) compared to VC
treated tumors (Figure 7F). This was supported by significantly reduced Ki67 reactivity
within the tissue (p = 0.0015), particularly for areas in close vicinity to necrosis (Figure 7G).
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Further, induction of apoptosis was observed in optCPE-transfected tumors, reflected by
significantly increased TUNEL positive nuclei (p = 0.0002) compared to VC treated control
tumors (Figure 7H). Of note, optCPE gene transfer was also shown to be effective in the
orthotopic setting, leading to tumor reduction of the Panc12536/eGFP-Luc PDX model
(Figure S4).
3.10. Combined CPE Oncoleaking Gene Therapy and Drug Treatment
The oncoleaking gene therapy holds promise for effective combination with con-
ventional therapies of PC. In fact, we addressed such a combinatorial approach in our
experiments by using the CPE-based gene therapy in combination with gemcitabine. In
this context we analyzed PC PDX treated with the standard of care drugs gemcitabine and
oxaliplatin regarding their Cldn3/4 expression. We showed, for the first time, a significant
induction of both Cldns in four drug-treated PDX models as first evidence for a drug-
induced upregulation of Cldn3/4. Of those, Panc12535 PDX showed the highest claudin
upregulation (Figure 8A). Due to this unexpected outcome, we performed an animal ex-
periment with single gemcitabine treatment, optCPE gene transfer or the combination of
both to exploit the drug-induced claudin upregulation for therapeutic synergy (Figure 8B).
The in vivo study in the Panc12535 model revealed a synergistic effect of combination of
optCPE based in vivo gene transfer and gemcitabine treatment. Here, tumor volume was
significantly reduced in tumors treated with the combination compared to the respective
controls. This indicates that gemcitabine is able to induce Cldn expression, which in turn
leads to a better target availability for CPE action. These findings warrant further validation
and open new perspectives for clinical use, as gemcitabine resistant tumors could be better
eradicated by combination with the novel oncoleaking strategy.
Cancers 2021, 13, x FOR PEER REVIEW 18 of 26 
 
 
topathological features (Figure 7). Primary tumors and respective PDX tissues were ana-
lyzed by HE staining. Pancreatic cancer PDX tissues were found to possess similar histo-
logical appearance as the corresponding primary tumor tissue: atypical glands, 
desmoplasia or pleomorphism of nuclei (Figure 7B). PCR expression analysis and Western 
blot of all 21 PDX models showed Cldn3/4 expression (Figure 7A). This was further con-
firmed by IHC for Cldn3/4, showing the specific membranous expression within the pan-
creatic cancer PDX tissue (Figure 7B). This is a strong indication that the target for CPE 
action is expressed in all of these pancreas cancers. 
 
Figure 7. Cont.







Cancers 2021, 13, 4393 20 of 26














Figure 7. In vivo optCPE gene therapy in patient derived xenograft (PDX) models of PC. (A) Claudin3/4 expression analysis
in 21 PC patient derived xenograft (PDX) models at mRNA and protein level (Figure S9). (B) Histopathology of primary
and xenograft tissue show similar histological appearance in representative models (upper two rows). Representative
images of Cldn3/4 expression (brown staining) in Panc9699, Panc9996, Panc10991, Panc11074 and Panc11495 PDX tumors
(C) in optCPE non-viral jet-injection (performed 21 days after PDX derived cell injection) transfected Panc12536/eGFP-Luc-
bearing mice significant antitumoral activity was observed. Significantly decreased tumor bioluminescence and (D) tumor
growth was determined in optCPE-expressing tumors compared to empty vector control (VC). (E) In optCPE-transfected
tumors reduced luminescence was measured compared to respective vector controls (VC), shown in representative images.
(F) Significant reduction of viability in optCPE-transfected tumors, determined by quantification of ex vivo bioluminescence
of tumors (representative bioluminescence images, lower panel). (G) The intratumoral optCPE gene transfer led to
significantly reduced Ki67 reactivity within tumor tissue compared to VC treated tissue. (H) In optCPE-transfected
Panc12536/eGFP-Luc PDX tumors the TUNEL assay revealed significantly increased number of TUNEL positive nuclei
compared to VC-transfected tumors. (* p < 0.05; ** p < 0.01: *** p < 0.001).
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4. Discussion
Pancreas carcinoma (PC) is one of the most lethal solid malignancies worldwide [36].
Despite therapeutic advances for PC treatment, the overall survival and prognosis of PC
patients at advanced stage remains dismal [37]. Therefore, we developed a novel treatment
concept of oncoleaking toxin-based gene therapy. We demonstrated the effective reduction
in PC growth in vitro and in vivo by CPE gene transfer, mediated by rapid membrane
disruption, associated with tumor cell apoptosis and necrosis.
An increasing number of in vitro and in vivo studies, which use bacterial toxins for
cancer treatment (e.g., diphtheria toxin, streptolysin O or Clostridium perfringens enterotoxin;
CPE) revealed their capability for effective cell killing [10,14]. The establishment of such
toxin-based therapy added novel features to cancer treatment, e.g., pore-formation (on-
coleaking). Recombinant CPE has demonstrated remarkable and selective cytotoxicity for
Cldn3/4 overexpressing epithelial tumors [38,39]. The association of altered Cldn expres-
sion and cancer development has been widely reported and there is increasing evidence
that dysregulation of tight junction proteins are important features in tumor pathology
and carcinogenesis [40]. Elevated Cldn expression level, particularly Cldn3/4, has been
reported in various types of solid cancer (e.g., PC, ovarian, breast, prostate and colon
cancer) [41–46]. Regarding the use of claudins for targeted gene therapy, overexpression
of claudin subtypes functioning as high affinity CPE-receptors—such as Cldn3/4—is an
important prerequisite. Our analyses for Cldn3/4 demonstrated their overexpression and
altered cellular distribution in the panel of human PC cell lines and PDX, with strong
membranous and cell–cell contact region, cytoplasmic as well as nuclear presence. This
points to an altered cellular distribution, in particular, mainly extrajunctional localization
of these claudins, which increases accessibility of these claudins for effective binding of
CPE [32]. This is a prerequisite for CPE-based tumor cell killing in vitro and in vivo. In
result of this, we determined a dose-dependent cytotoxic effect of recombinant and gene
transfected CPE in all PC cell lines, which was positively correlated with the level of
Cldn expression. Many studies have described the highly specific interaction of CPE and
Cldn3/4, which is essential for selective tumor cell killing [29,30,33,47–49]. Selectivity and
dependency on claudin availability of CPE-mediated cytotoxicity was supported by our
RNAi experiments, where downregulation of the claudins prevents CPE cytotoxicity.
Structure-based mutagenesis enabled design of CPE mutants that also target claudins
such as Cldn1 or -5 that are not high affinity receptors for CPE wildtype. Local injection
of these recombinant CPE mutants strongly reduced growth of Cldn1-expressing thyroid
tumors in CDX models [33]. CPE mutants can be used also for gene transfer to further
adjust the targeted claudins to the claudin subtype expression profile of a given tumor
entity.
Here we focused on the mechanisms mediated by CPE gene transfer for suicide
gene therapy. Our analyses revealed that CPE gene transfer induced rapid fragmenta-
tion of nuclei, massive cell swelling, membrane blebbing and formation of membrane
vesicles, release of LDH, increased Ca2+ influx, activation of caspases and calpain. This
suggests, that CPE gene transfer induces different cell death mechanisms, known as
“apoptosis-necrosis continuum” [50], which are independent of extent of pore formation.
Matsuda et al. and Chakrabarti et al. demonstrated that low CPE doses result in formation
of low numbers of membrane pores. This causes limited Ca2+ influx [22,51], which triggers
caspase-3-mediated cell death by calpain protease activation and results in apoptosis. Two
defined factors have been identified that convert an ongoing apoptosis to a necrosis: the
availability of intracellular ATP and of caspases [50,52,53]. During apoptosis membrane
integrity is maintained until late stages of this process, whereas strong release of LDH is
an early event in necrosis [29,30]. Our findings not only support the rapid and effective
cell killing by CPE gene transfer via apoptotic and necrotic signaling, they also provide the
basis for novel combination approaches to exploit the CPE effects for combination with
drugs, which also trigger apoptotic signaling.
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For efficient cell killing the bystander effect is supportive in gene therapy. Our im-
munofluorescence analysis in optCPE-transfected cells revealed vesicle like accumulations
as indication for exocytosis. Further, membrane budding was observed, representing
a key step in vesicular transport, multivesicular body and exosome formation. Indeed,
we showed that CPE is released from cells and is also liberated via exosomes after CPE
gene transfer and is acting on neighboring cancer cells. The recent study of Shrestha and
colleagues also confirmed a bystander killing mechanism of native and recombinant CPE
protein [54]. They demonstrated that supernatants collected from a CPE treated sensitive
cell kills other cells that are insensitive toward the toxin. However, they explain this effect
by release of factors such as caspase-3 or LDH. By contrast, as we described previously
and showed in this study, liberated CPE itself is present in the media of CPE-transfected
cells. This is independent of CPE-mediated cytotoxicity or Cldn3/4 expression, as it was
also released by the Cldn-negative SK-MEL-5 cells [29,30]. Therefore, two mechanisms
contribute to the bystander effect: transmembranous and exosomal release of CPE, which in
turn acts on neighboring, non-transfected cancer cells. Such bystander effect is of particular
importance for the in vivo use of the CPE gene transfer.
Our study evaluated the anticancer potential of CPE gene therapy in different luciferase-
expressing CDX and PDX models. Such locally applied toxin-based gene therapy has been
successfully tested for diphtheria toxin in human PSA positive prostate xenograft tu-
mors [55]. In our previous study, we demonstrated selective and efficient antitumoral
efficacy of CPE gene therapy in Cldn3/4 overexpressing colon cancer PDX [30]. In this
study, CPE gene transfer was effective in inducing massive intratumoral necrosis and
induction of apoptosis in tissue areas in close vicinity to necrosis in subcutaneous and
also orthotopic CDX and PDX PC models. This is in line with results of others, where
necrosis was observed after local in vivo application of recombinant CPE [23,28,33,56,57].
Furthermore, the inclusion of a binding-deficient mutated optCPE (mutCPE) construct
(CPE-Y306A/L315A) clearly showed the selectivity of tumor cell killing in vivo pointing to
the targeted action of CPE gene therapy. More importantly, in all in vivo CPE therapies we
did not observe severe side effects nor body weight losses in the animals. This indicated
good tolerability of the CPE gene therapy, as also described previously [28–30].
In this study, we also evaluated the potential of CPE gene transfer in combination
with drug treatments. In this context, we determined a drug treatment-induced increase
of Cldn3/4 expression. Due to this unexpected result, we performed combination studies
with gemcitabine and CPE gene transfer, which demonstrated a synergistic effect of this
combination. This implied that gemcitabine can induce Cldn expression, which in turn
leads to an improved target availability for CPE gene therapy as a basis for new combination
approaches in PC therapy.
5. Conclusions
In summary we established the efficient use of oncoleaking optCPE suicidal gene
therapy in vitro, and more importantly, in subcutaneous and orthotopic human pancreatic
cancer CDX and PDX models in vivo. The study emphasizes the great potential of this
novel strategy, as it is selective for therapy of pancreas carcinoma.
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.3390/cancers13174393/s1, Figure S1: Model of CPE bound to claudin-4, Figure S2: Cldn-dependence
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optCPE gene transfer on apoptotic signaling by human apoptosis array, Figure S4: Oncoleaking
in vivo effect of optCPE suicidal gene therapy in orthotopic human pancreatic cancer PDX model,
Figure S5: Original Western blots of Figure 1, Figure S6: Original Western blots of Figure 2, Figure S7:
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culture medium at indicated time points after optCPE gene transfer.
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